2026 Q1 -tulosraportti
35 päivää sitten
‧39 min
6,75 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 56 | - | - | ||
| 1 523 | - | - | ||
| 2 | - | - | ||
| 43 | - | - | ||
| 3 108 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 8 996 530 | 8 996 530 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 8 996 530 | 8 996 530 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 29.1. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 25.7.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
4 t sitten4 t sittenIm a longstanding owner of this stock. How do I get to purchase this stock through nordnet at the price of 2.45 as promised?
·3 t sitten18 (not 1800) for each share that was owned as of 9/6.
·4 t sittenCEO's Comments The first quarter marks an important turning point for Peptonic. After a long and demanding reconstruction process, the company now stands stronger, more focused, and with full focus on the future. The fact that we have successfully gone through this process not only means increased stability – it also gives us the right conditions to accelerate development and create long-term shareholder value. Over the past year, we have implemented extensive changes to streamline operations, optimize the organization, and lower the cost base. The result is a significantly more cost-effective company with a clearer structure and better scalability. Today, we have an organization that is better adapted to our strategic goals and that creates a stable foundation for sustainable growth and improved profitability going forward. Our focus moving forward is clear: stronger products, increased sales, and continued brand building. The core of Peptonic is our proprietary portfolio in intimate women's health – a segment with strong growth potential and increasing global demand. We see great opportunities to continue gaining market share with our existing products while actively broadening the product portfolio to meet more consumer needs. An important step in this strategy is the communicated launch of two new products within our VagiVital brand, VagiVital Intimate V Wipes and VagiVital Moisturizing Intimate Cream. The launches strengthen our position in intimate care and are part of our ambition to develop VagiVital into a broader and stronger brand with relevance in women's everyday lives. At the same time, we continue to invest in marketing, digital presence, and a more diversified sales structure to create scalable and long-term growth. We are already seeing concrete results from our strategic initiatives. The Norwegian consumer market has developed strongly and has gone from low levels to now constituting a significant part of our e-commerce sales. This shows that our products and our business model have the potential to grow in new markets as well. At the same time, partner sales remain uneven between quarters, as larger orders and deliveries occur periodically, which affects short-term sales performance. We also view positively the upcoming warrants with an exercise period during the first half of June. Upon full exercise, these can provide the company with a significant capital injection, which would further strengthen our financial position and enable increased investments in growth, product development, and market expansion. We are also pleased with the ongoing strong support we receive from our largest shareholder, which is an important sign of strength and a testament to the confidence in the company's strategy and future potential. In parallel, work continues to ensure the right competence and organization for the next phase of the company's development. Peptonic is now entering the next phase with a clearer strategic focus, improved financial conditions, and an organization equipped for the future. We have carried out extensive change work and are today better positioned to create sustainable growth and long-term value for our shareholders. We look forward to the future with great confidence and to continuing our journey together with both existing and new investors. Daniel Rudeklint Interim CEO Peptonic Medical AB
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
35 päivää sitten
‧39 min
6,75 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- 4 t sitten4 t sittenIm a longstanding owner of this stock. How do I get to purchase this stock through nordnet at the price of 2.45 as promised?·3 t sitten18 (not 1800) for each share that was owned as of 9/6.
- ·4 t sittenCEO's Comments The first quarter marks an important turning point for Peptonic. After a long and demanding reconstruction process, the company now stands stronger, more focused, and with full focus on the future. The fact that we have successfully gone through this process not only means increased stability – it also gives us the right conditions to accelerate development and create long-term shareholder value. Over the past year, we have implemented extensive changes to streamline operations, optimize the organization, and lower the cost base. The result is a significantly more cost-effective company with a clearer structure and better scalability. Today, we have an organization that is better adapted to our strategic goals and that creates a stable foundation for sustainable growth and improved profitability going forward. Our focus moving forward is clear: stronger products, increased sales, and continued brand building. The core of Peptonic is our proprietary portfolio in intimate women's health – a segment with strong growth potential and increasing global demand. We see great opportunities to continue gaining market share with our existing products while actively broadening the product portfolio to meet more consumer needs. An important step in this strategy is the communicated launch of two new products within our VagiVital brand, VagiVital Intimate V Wipes and VagiVital Moisturizing Intimate Cream. The launches strengthen our position in intimate care and are part of our ambition to develop VagiVital into a broader and stronger brand with relevance in women's everyday lives. At the same time, we continue to invest in marketing, digital presence, and a more diversified sales structure to create scalable and long-term growth. We are already seeing concrete results from our strategic initiatives. The Norwegian consumer market has developed strongly and has gone from low levels to now constituting a significant part of our e-commerce sales. This shows that our products and our business model have the potential to grow in new markets as well. At the same time, partner sales remain uneven between quarters, as larger orders and deliveries occur periodically, which affects short-term sales performance. We also view positively the upcoming warrants with an exercise period during the first half of June. Upon full exercise, these can provide the company with a significant capital injection, which would further strengthen our financial position and enable increased investments in growth, product development, and market expansion. We are also pleased with the ongoing strong support we receive from our largest shareholder, which is an important sign of strength and a testament to the confidence in the company's strategy and future potential. In parallel, work continues to ensure the right competence and organization for the next phase of the company's development. Peptonic is now entering the next phase with a clearer strategic focus, improved financial conditions, and an organization equipped for the future. We have carried out extensive change work and are today better positioned to create sustainable growth and long-term value for our shareholders. We look forward to the future with great confidence and to continuing our journey together with both existing and new investors. Daniel Rudeklint Interim CEO Peptonic Medical AB
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 56 | - | - | ||
| 1 523 | - | - | ||
| 2 | - | - | ||
| 43 | - | - | ||
| 3 108 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 8 996 530 | 8 996 530 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 8 996 530 | 8 996 530 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 29.1. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 25.7.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
2026 Q1 -tulosraportti
35 päivää sitten
‧39 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 29.1. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 25.7.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
6,75 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- 4 t sitten4 t sittenIm a longstanding owner of this stock. How do I get to purchase this stock through nordnet at the price of 2.45 as promised?·3 t sitten18 (not 1800) for each share that was owned as of 9/6.
- ·4 t sittenCEO's Comments The first quarter marks an important turning point for Peptonic. After a long and demanding reconstruction process, the company now stands stronger, more focused, and with full focus on the future. The fact that we have successfully gone through this process not only means increased stability – it also gives us the right conditions to accelerate development and create long-term shareholder value. Over the past year, we have implemented extensive changes to streamline operations, optimize the organization, and lower the cost base. The result is a significantly more cost-effective company with a clearer structure and better scalability. Today, we have an organization that is better adapted to our strategic goals and that creates a stable foundation for sustainable growth and improved profitability going forward. Our focus moving forward is clear: stronger products, increased sales, and continued brand building. The core of Peptonic is our proprietary portfolio in intimate women's health – a segment with strong growth potential and increasing global demand. We see great opportunities to continue gaining market share with our existing products while actively broadening the product portfolio to meet more consumer needs. An important step in this strategy is the communicated launch of two new products within our VagiVital brand, VagiVital Intimate V Wipes and VagiVital Moisturizing Intimate Cream. The launches strengthen our position in intimate care and are part of our ambition to develop VagiVital into a broader and stronger brand with relevance in women's everyday lives. At the same time, we continue to invest in marketing, digital presence, and a more diversified sales structure to create scalable and long-term growth. We are already seeing concrete results from our strategic initiatives. The Norwegian consumer market has developed strongly and has gone from low levels to now constituting a significant part of our e-commerce sales. This shows that our products and our business model have the potential to grow in new markets as well. At the same time, partner sales remain uneven between quarters, as larger orders and deliveries occur periodically, which affects short-term sales performance. We also view positively the upcoming warrants with an exercise period during the first half of June. Upon full exercise, these can provide the company with a significant capital injection, which would further strengthen our financial position and enable increased investments in growth, product development, and market expansion. We are also pleased with the ongoing strong support we receive from our largest shareholder, which is an important sign of strength and a testament to the confidence in the company's strategy and future potential. In parallel, work continues to ensure the right competence and organization for the next phase of the company's development. Peptonic is now entering the next phase with a clearer strategic focus, improved financial conditions, and an organization equipped for the future. We have carried out extensive change work and are today better positioned to create sustainable growth and long-term value for our shareholders. We look forward to the future with great confidence and to continuing our journey together with both existing and new investors. Daniel Rudeklint Interim CEO Peptonic Medical AB
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 56 | - | - | ||
| 1 523 | - | - | ||
| 2 | - | - | ||
| 43 | - | - | ||
| 3 108 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 8 996 530 | 8 996 530 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 8 996 530 | 8 996 530 | 0 | 0 |